Legend Biotech (LEGN) Total Liabilities (2019 - 2026)

Legend Biotech (LEGN) has reported Total Liabilities for 8 consecutive years, with $629.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 5.2% year-over-year to $629.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.0 million (up 5.2% YoY) and the FY2025 annual result came in at $731.6 million, up 16.2% from the prior year.
• Total Liabilities declined to $629.0 million in Q1 2026 per LEGN's latest filing, from $731.6 million in the prior quarter.
• Over the last five years, Total Liabilities for LEGN reached as high as $731.6 million in Q4 2025 and fell as low as $499.7 million in Q3 2023.
• A 5-year average of $612.0 million and a median of $611.0 million in 2024 frame the typical range for Total Liabilities.
• The largest YoY upside for Total Liabilities was 65.95% in 2022 against a maximum downside of 99.85% in 2022.
• Year by year, Total Liabilities stood at $586.7 million in 2022, then advanced by 1.8% to $597.2 million in 2023, then gained by 5.42% to $629.6 million in 2024, then advanced by 16.2% to $731.6 million in 2025, then dropped by 14.02% to $629.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $629.0 million, $731.6 million, and $701.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.